JP2003528100A5 - - Google Patents

Download PDF

Info

Publication number
JP2003528100A5
JP2003528100A5 JP2001568941A JP2001568941A JP2003528100A5 JP 2003528100 A5 JP2003528100 A5 JP 2003528100A5 JP 2001568941 A JP2001568941 A JP 2001568941A JP 2001568941 A JP2001568941 A JP 2001568941A JP 2003528100 A5 JP2003528100 A5 JP 2003528100A5
Authority
JP
Japan
Prior art keywords
cabergoline
toluene
diethyl ether
ether mixture
resulting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001568941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003528100A (ja
JP4184666B2 (ja
Filing date
Publication date
Priority claimed from GBGB0007308.0A external-priority patent/GB0007308D0/en
Application filed filed Critical
Publication of JP2003528100A publication Critical patent/JP2003528100A/ja
Publication of JP2003528100A5 publication Critical patent/JP2003528100A5/ja
Application granted granted Critical
Publication of JP4184666B2 publication Critical patent/JP4184666B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001568941A 2000-03-24 2001-03-19 カベルゴリンの結晶性形態iを調製するための方法 Expired - Fee Related JP4184666B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0007308.0A GB0007308D0 (en) 2000-03-24 2000-03-24 Process for preparing crystalline form | of cabergoline
GB0007308.0 2000-03-24
PCT/EP2001/003099 WO2001070740A1 (en) 2000-03-24 2001-03-19 Process for preparing crystalline form i of cabergoline

Publications (3)

Publication Number Publication Date
JP2003528100A JP2003528100A (ja) 2003-09-24
JP2003528100A5 true JP2003528100A5 (https=) 2006-01-05
JP4184666B2 JP4184666B2 (ja) 2008-11-19

Family

ID=9888433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001568941A Expired - Fee Related JP4184666B2 (ja) 2000-03-24 2001-03-19 カベルゴリンの結晶性形態iを調製するための方法

Country Status (31)

Country Link
US (2) US6727363B2 (https=)
EP (1) EP1272489B1 (https=)
JP (1) JP4184666B2 (https=)
KR (1) KR100827558B1 (https=)
CN (1) CN1188412C (https=)
AR (1) AR032449A1 (https=)
AT (1) ATE250601T1 (https=)
AU (2) AU780747B2 (https=)
BR (1) BR0109507A (https=)
CA (1) CA2402836A1 (https=)
CZ (1) CZ20023176A3 (https=)
DE (1) DE60100858T2 (https=)
DK (1) DK1272489T3 (https=)
EA (1) EA005928B1 (https=)
EE (1) EE05088B1 (https=)
ES (1) ES2208602T3 (https=)
GB (1) GB0007308D0 (https=)
HK (1) HK1052348B (https=)
HU (1) HUP0300591A3 (https=)
IL (2) IL150985A0 (https=)
MX (1) MXPA02009283A (https=)
MY (1) MY134189A (https=)
NO (1) NO20024321D0 (https=)
NZ (1) NZ521316A (https=)
PE (1) PE20011140A1 (https=)
PL (1) PL358253A1 (https=)
PT (1) PT1272489E (https=)
SI (1) SI1272489T1 (https=)
SK (1) SK13582002A3 (https=)
WO (1) WO2001070740A1 (https=)
ZA (1) ZA200206045B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007307D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
IL163779A0 (en) * 2002-03-15 2005-12-18 Pharmacia Corp Process for preparing crystalline form i of cabergoline
PL374503A1 (en) * 2002-03-15 2005-10-31 Pharmacia Corporation Process for preparing crystalline form i of cabergoline
IL155545A (en) 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
KR20060028761A (ko) 2003-05-08 2006-04-03 아이박스 파마슈티컬스 에스.알.오. 다형의 카베르골린
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
GB0515430D0 (en) * 2005-07-27 2005-08-31 Resolution Chemicals Ltd Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
EP1925616A1 (en) * 2006-10-26 2008-05-28 LEK Pharmaceuticals D.D. Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
US8637099B2 (en) * 2007-08-29 2014-01-28 Max Zeller Sohne Ag Use of Vitex agnus castus extracts for preparing a medicament
EP4074552B1 (en) * 2021-04-16 2024-04-03 Thermo King LLC Electrical connection unit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019322A1 (de) 1980-05-21 1981-12-03 Merck Patent Gmbh, 6100 Darmstadt Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) * 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB9205439D0 (en) * 1992-03-12 1992-04-22 Erba Carlo Spa Process for the synthesis of ergoline derivatives
WO1995005176A1 (en) 1993-08-18 1995-02-23 Alcon Laboratories, Inc. Use of ergoline derivatives for the treatment of glaucoma
JP2002509119A (ja) 1998-01-13 2002-03-26 アストラゼネカ ユーケイ リミテッド ドーパミン(D2)レセプターアゴニスト活性を有する化合物およびβ2−アドレナリンレセプターアゴニスト活性を有する化合物(B)を含有する薬学的組成物
JP2002507562A (ja) 1998-03-27 2002-03-12 ファルマシア・アンド・アップジョン・カンパニー レストレスレッグ症候群の治療におけるカベルゴリンの使用
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline

Similar Documents

Publication Publication Date Title
JP2003528100A5 (https=)
CN106315625B (zh) 复合生产高纯单水氢氧化锂、高纯碳酸锂和电池级碳酸锂的方法
RO116276B1 (ro) Procedeu de purificare a melaminei
RU2003111948A (ru) Способы получения кристаллов в-типа натеглинида
JP2005509025A5 (https=)
WO2000031014A8 (en) Process of purifying and producing high purity aromatic polycarboxylic acids and derivatives thereof
CN105541953B (zh) 一种高纯度奥贝胆酸的重结晶纯化方法
KR880002847A (ko) 형태학적으로 균일한 형태를 갖는 티아졸 유도체의 제조방법
JPH11124372A5 (https=)
CN113979987A (zh) 一种高纯碳酸乙烯酯的提纯装置和方法
CN109133467B (zh) 一种回收酸化法生产烟酸的洗涤水中烟酸和氯化铵的方法
CN102502530A (zh) 静态熔融结晶生产电子级硫酸的方法
JPS62256705A (ja) 高純度窒化珪素前駆物質の製造方法
CA1056835A (en) Process for recovering nicotinic amide
EP2374786A1 (en) Purification of monochloroacetic acid rich streams
JPH0669889B2 (ja) 層状ケイ酸塩の水熱合成法
US2734058A (en) Process for the production of solid finely
JP2002506064A5 (https=)
RU2131843C1 (ru) Способ получения кремния высокой чистоты
JPH0361605B2 (https=)
CN1308013A (zh) 无水硫化钠晶体的制备方法
JPH0254820B2 (https=)
US2490633A (en) Purification of ammonium beryllium fluoride
CN1084299C (zh) 氯化钾和硫酸铵混合直接加热生产硫酸钾的方法
KR20190056265A (ko) 층상형 MnBi, MnBi 나노시트 및 이들의 제조방법